Table 1.
Clinicopathological features in the propensity-score matched population.
| Clinicopathological features | TOT, N = 158 | AT, N = 79 | AT-Cb, N = 79 | P | ||||
|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | |||
| Age years, median (range) | 54 (43–61) | 51 (42–61) | 54 (45–61) | 0.495 | ||||
| Histotype | ductal/NOS | 154 | 97.5% | 77 | 97.5% | 77 | 97.5% | 1.000 |
| lobular/other | 4 | 2.5% | 2 | 2.5% | 2 | 2.5% | ||
| cT | T1 | 24 | 15.2% | 11 | 13.9% | 13 | 16.5% | 0.904 |
| T2 | 112 | 70.9% | 57 | 72.2% | 55 | 69.6% | ||
| T3–T4 | 22 | 13.9% | 11 | 13.9% | 11 | 13.9% | ||
| cN | Negative | 80 | 50.6% | 41 | 51.9% | 39 | 49.4% | 0.750 |
| Positive | 78 | 49.4% | 38 | 48.1% | 40 | 50.6% | ||
| Grade | G2 | 9 | 5.7% | 6 | 7.6% | 3 | 3.8% | 0.303 |
| G3 | 149 | 94.3% | 73 | 92.4% | 76 | 96.2% | ||
| Ki67 %, median (range) | 60 (42–78) | 60 (35–75) | 65 (50–80) | 0.172 | ||||
| TILs %, median (range) | 13 (1–30) | 10 (3–40) | 15 (1–30) | 0.899 | ||||
| BRCA | wt or unknown | 134 | 84.8% | 66 | 83.5% | 68 | 86.1% | 0.658 |
| Mut | 24 | 15.2 | 13 | 16.5% | 11 | 13.9% | ||
Clinicopathological features in the overall propensity-score matched population, and in the subgroups of patients treated with anthracycline-taxane (AT, n = 79) and with the addition of Carboplatin (AT-Cb, n = 79).